Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular and Clinical Neurophysiology (EMG) Posters (7:00 AM-5:00 PM)
123
To review the literature on Guillain Barre Syndrome (GBS) as a complication of COVID-19, examine factors contributing to clinical presentations and summarize the pathophysiologic mechanisms that might be implicated in the development of such complications. 
GBS has been linked to different coronavirus strains as MERS-CoV and Zika. In January 2020, the first case of GBS due to COVID-19 was documented in China. However, the increasing reports of GBS cases haven’t yet been determined to be para-infectious or postinfectious complications of COVID-19 infection. 
We have searched MEDLINE, EMBASE, and COCHRANE databases and identified 45 case reports and 12 case series. The following keywords were used: Guillain Barre Syndrome, GBS, Miller Fisher syndrome, MFS, SARS-CoV2 and COVID-19.  These cases were summarized in a table showing demographics, clinical presentations, investigations, and global distribution of the cases. 

The total number of reported cases was 84. 53 cases had positive COVID-19 PCR at the time of diagnosis. Only four cases showed positive antiganglioside antibodies. Most of the cases had albumino-cytologic dissociation. Only 33 cases have anosmia and dysgeusia mentioned in their reports, and they were present prior to GBS diagnosis in 16 cases. Almost all cases received intravenous immunoglobulins (IVIG) or Plasmapheresis (PLEX) and most of the case has shown clinical improvement. 12 cases didn’t show improvement, and 9 cases were complicated by progressive respiratory failure. 
GBS cases are likely to increase in the future as complications of COVID-19. GBS in particular is a critical complication in COVID-19, as it can lead to respiratory failure, which directly affects clinical outcomes. Further studies are needed to identify whether these neurologic complications are directly related to COVID-19 infection, or they are a part of a post-infectious syndrome.
Authors/Disclosures
Mohammad Aladawi, MD
PRESENTER 		Dr. Aladawi has nothing to disclose.
Mohamed Elfil, MBBCh Dr. Elfil has nothing to disclose.
Baha Abu-Esheh, MD, FÂ鶹´«Ã½Ó³»­ (Neurology Care) Dr. Abu-Esheh has received personal compensation for serving as an employee of BAHA Abu-eager, MD PC. Dr. Abu-Esheh has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan. Dr. Abu-Esheh has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Amgen. Dr. Abu-Esheh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lilly.
Deaa Abu-Jazar, MD (UTMB Health - Galveston) Dr. Abu-Jazar has nothing to disclose.
Ahmad Armouti, MD (USF) Dr. Armouti has nothing to disclose.
Ahmed A. Bayoumi, MD (McGovern Medical School) Dr. Bayoumi has nothing to disclose.
Ezequiel A. Piccione, MD, FÂ鶹´«Ã½Ó³»­ (UNMC) Dr. Piccione has nothing to disclose.